Company Overview of Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California.
409 Illinois Streeet
San Francisco, CA 94158
Founded in 2008
Key Executives for Carmot Therapeutics, Inc.
Co-Founder and Chief Executive Officer
Vice President of Business Development
Compensation as of Fiscal Year 2014.
Carmot Therapeutics, Inc. Key Developments
Carmot Therapeutics, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM
Jun 17 14
Carmot Therapeutics, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.
Carmot Therapeutics Names Dave Jobes, PhD as Vice President of Business Development
Jun 16 14
Carmot Therapeutics reported that Dave Jobes, PhD, has joined the company as vice president of business development. Jobes brings nearly 15 years of biopharmaceutical industry experience to Carmot from such diverse areas as diagnostics, vaccines, and small molecule therapeutics. Prior to joining Carmot, Jobes headed his own consulting firm focused on assisting clients with transactional work and business development strategies. Previously, he was co-founder and vice president of business development at Presidio Pharmaceuticals. Jobes will be leading the company's partnering efforts around its internal programs in diabetes and cancer, its proprietary lead-identification technology, Chemotype Evolution, and Tethering, to which Carmot has an exclusive license.
Carmot Therapeutics, Inc. Enters into Collaboration and License Agreement with Amgen Inc
Jan 20 14
Carmot Therapeutics, Inc. has entered into a collaboration and license agreement with Amgen, Inc. During the collaboration Carmot will apply its proprietary Chemotype Evolution to discover novel drug leads for two targets selected by Amgen. Carmot and Amgen will work together to identify and optimize drug candidates, while Amgen will be solely responsible for their clinical development. Under the terms of the agreement, Carmot will receive an upfront payment, research funding, and preclinical and clinical milestone payments. In addition, a royalty will be paid on commercial sales of products emerging from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|